Skip to content
Taxonomy
Statement from CMTA’s Chief Executive Officer, Sue Bruhn, PhD
Dear Members of the CMT Community, The Charcot-Marie-Tooth Association (CMTA) Read More
CMTA-STAR Clinical Expert Board Co-Chair Prof. Mary Reilly Honored with Prestigious MBE
The Charcot-Marie-Tooth Association proudly celebrates Professor Mary M. Reilly, MD, Read More
CMT-SORD: Bringing the Science Down to Earth | Shooting Star Ep. 3
Shooting Star brings science down to Earth, making complex CMT Read More
Learn How CMTA is Accelerating Research and Empowering Patients
The Charcot-Marie-Tooth Association (CMTA) is transforming the future of CMT Read More
CMTA Invests $423K to Accelerate CMT Diagnostics and Gene Discovery
CMTA announced today a $423,000 investment to address diagnostic gaps Read More
Simply CMT Podcast Episode 2: Jonah Berger
Welcome to Episode 2 of the Simply CMT Podcast! Join Read More
Encouraging News in CMT Research from CMTA-STAR Alliance Partner Alesta Therapeutics
Alesta Therapeutics, a CMTA-STAR Alliance Partner focused on developing therapies Read More
CMTA’s New Video Aims to Increase Awareness About CMT
Charcot-Marie-Tooth disease (CMT) is the most common inheritable peripheral neuropathy, Read More
Nervosave: Shaping the Future of Genetic Therapy for CMT1A
What is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics, Read More
CMTA-STAR Alliance Partner NMD Pharma Announces FDA Orphan Drug Designation for NMD670
NMD Pharma A/S, a CMTA-STAR Alliance Partner, recently announced that Read More
